Broadly stated, the IORA CCOP exists to further the progress in preventing, detecting, treating, recovering from, and curing cancer. Specifically, the IORA CCOp seeks to improve outcomes for cancer victims in central Illinois; add to the knowledge of the efficacy of known and new cancer treatments; educate the health care professions and the general public of the importance of prevention, early detection, and proper treatment of cancer; and finally, improve accessibility to cancer treatments and methodologies. The IORA CCOP and its affiliates offer nationally based research protocols to patients in a 17-county catchment area (population 960,000+). This area spans nearly 12,000 square miles of mostly rural country. The affiliates make possible the achievement of the IORA's goals. Because of these 20 sites, most people are within an hour's drive (and often much less) of the most current cancer protocols and cancer related technologies such as SPECT, MRI, CT scan, and radiation therapy. Through the affiliates the IORA CCOP draws protocol enrollees from a large section of the state. Because cancer patients are seen in the affiliate's community, the oncologist closely coordinates patient care with the hometown doctor. This permits the extension of the specialist's cancer care expertise to the front line physician. A broad referral network among the affiliates, the IoRA, Midwest Radiation Therapy Consultants, Ltd.s and two larger component hospitals supports patient protocol enrollment, transfer of research knowledge, and professional and community participation in cancer education. The IORA CCOP uses research designs and protocols from the North Central Cancer Treatment Group, Eastern Cooperative Oncology Group, Radiation Therapy Treatment Group, and the National Cancer Institute. Since 1982, IORA CCOP has enjoyed an excellent working relationship with these groups. The IORA protocol review system at two component hospitals, the American College of Surgeons certified computerized cancer registry, the cancer coordinating committee, IORA data management coordination, a centralized patient log and quality control systems, and a high level of IORA oncology team commitment to CCOP support research methodologies. Through the already established programs, the IORA CCOP expects to continue to accrue patients to support research protocols while at the same time providing excellent cancer care to the people of central Illinois.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035113-09
Application #
3557511
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1983-09-01
Project End
1994-05-31
Budget Start
1992-06-01
Budget End
1993-05-31
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Methodist Medical Center of Illinois
Department
Type
DUNS #
City
Peoria
State
IL
Country
United States
Zip Code
61636
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Apoe, Ogheneruona; Jung, Sin-Ho; Liu, Heshan et al. (2016) Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. Am J Hematol Oncol 12:4-9
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Zhao, Yujie; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol 10:172-80
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Rule, William G; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol 6:119-26

Showing the most recent 10 out of 165 publications